


### **Amendments to the Claims:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1. (Currently Amended) A topical ophthalmic composition comprising a carrier and a pharmaceutical conjugate comprising an ophthalmically useful therapeutic component covalently coupled to an efficacy enhancing component effective in delivering the conjugate to a posterior portion of an eye of an individual when the composition is topically administered to the eye, the efficacy enhancing component having the formula A:




wherein X is




~~R1, R2~~, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker, wherein at least one of R3, R4, R5, R6, R7, R8, R9, R10

and R11 is a linker and the linker joins the therapeutic component and the efficacy enhancing component.


2. (Previously presented) A composition of claim 1 wherein the therapeutic component and the efficacy enhancing component are directly joined by a covalent bond, and the carrier comprises a liquid.
3. (Previously presented) A composition of claim 1 wherein the therapeutic component and the efficacy enhancing component are joined by a linker.
4. (Currently Amended) A composition of claim 1 wherein ~~R1 and R2 are Hs,~~ and R3 is a linker.
5. (Previously presented) A composition of claim 1 wherein the efficacy enhancing component is a memantine.
6. (Previously presented) A composition of claim 1 wherein the linker is selected from the group consisting of:




Linker B




Linker C




Linker D




Linker E



Linker F



Linker G



Linker H

wherein R<sub>12</sub> is an H or a C<sub>1</sub>-C<sub>10</sub> hydrocarbon, m = 0 to 10, and n = 0 to 10.

7. (Previously presented) A pharmaceutical conjugate of claim 1 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics,

anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, tyrosine kinase inhibitors and neuroprotectants.

8. (Previously presented) A composition of claim 1 wherein the therapeutic component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6- (2-imidazolyl-2-ylamino) quinoxaline, and mixtures thereof.

9. (Cancelled) A composition of claim 1 wherein the efficacy enhancing component comprises a memantine, and the conjugate further comprises a linker joining the therapeutic component and the memantine.

10. (Withdrawn) A pharmaceutical conjugate of claim 1 wherein the therapeutic component comprises a timolol and the efficacy enhancing component comprises a memantine, and the conjugate further comprises a linker joining the timolol and the memantine.

11. (Cancelled) A composition of claim 8 further comprising a memantine, and a linker joining the therapeutic component and the memantine.


12. (Previously presented) A composition of claim 1 wherein the therapeutic component and the efficacy enhancing component disassociate under physiological conditions.

13. (Cancelled)


14. (Previously presented) A composition of claim 1 wherein the conjugate has an aqueous solubility, a partition coefficient and/or an affinity for melanin that is greater relative to a compound comprising the same therapeutic component which is not joined to an efficacy enhancing component.

15. (Previously presented) A composition of claim 1 wherein the conjugate is a salt.


16. (Currently Amended) A topical ophthalmic composition comprising a carrier and a pharmaceutical conjugate comprising an ophthalmically useful therapeutic component covalently coupled to an efficacy enhancing component effective in delivering the conjugate to a posterior portion of an eye of an individual when the composition is topically administered to the eye, the efficacy enhancing component having the formula A:




wherein X is




~~R1, R2~~, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker; the linker is selected from the group consisting of :




Linker B




Linker C




Linker D




Linker E



Linker F



Linker G




Linker H


wherein R<sub>12</sub> is an H or a C<sub>1</sub>-C<sub>10</sub> hydrocarbon, m = 0 to 10, and n = 0 to 10.

17-23. (Cancelled)


24. (Currently Amended) An ophthalmic composition comprising a carrier and a pharmaceutical conjugate comprising an ophthalmically useful quinoxaline component-containing therapeutic component covalently coupled to an efficacy enhancing component effective in delivering the conjugate to a posterior segment of an eye of an individual when the composition is topically administered to the eye, the efficacy enhancing component having the formula A:




wherein X is




R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker; the linker is selected from the group consisting of:




Linker B




Linker C




Linker D




Linker E



Linker F



Linker G



Linker H

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to 10, and n = 0 to 10.

25. (Previously presented) The composition of claim 24 wherein the therapeutic component is selected from the group consisting of quinoxaline, (2-imidazolin-2-



ylamino) quinoxaline, 5-bromo-6- (2-imidozolin-2-ylamino) quinoxaline, and mixtures thereof.

26. (Previously presented) The composition of claim 25 wherein the therapeutic component comprises brimonidine tartrate.